Topotecan

Generic Name: Topotecan

Brand Names: Hycamtin, Potactasol, Topotecan Hospira

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₃N_₃O_₅

CAS Number: 123948-87-8

Unique Ingredient Identifier: 7M7YKX2N15

Background: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.

Indication: 用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。

Associated Conditions: Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)

Associated Therapies: -

Clinical Trials

Oral Topotecan Versus Docetaxel in Second-Line Treatment of Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2005-09-19

Last Posted Date: 2010-06-28

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 80

Registration Number: NCT00193245

Locations: 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States

Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colon Cancer

First Posted Date: 2005-09-19

Last Posted Date: 2011-05-03

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 40

Registration Number: NCT00193167

Locations: 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States

Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma

Phase 2

Completed

Conditions: Ovary Cancer

First Posted Date: 2005-09-19

Last Posted Date: 2011-05-03

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 50

Registration Number: NCT00193297

Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse

Phase 2

Completed

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Malignant Tumor of Peritoneum

First Posted Date: 2005-09-19

Last Posted Date: 2011-02-25

Lead Sponsor: ARCAGY/ GINECO GROUP

Target Recruit Count: 165

Registration Number: NCT00189566

Locations: 🇫🇷
Hôpital Hotel Dieu, Paris, France

Weekly Topotecan in Combination With Carboplatin in Two Different Schedules for Refractory and/or Advanced Solid Tumors

Phase 1

Completed

Conditions: Cancer

First Posted Date: 2005-09-19

Last Posted Date: 2011-05-04

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 18

Registration Number: NCT00193583

Locations: 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States

Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma

Phase 1

Completed

Conditions: Ovarian Cancer

First Posted Date: 2005-09-16

Last Posted Date: 2016-12-01

Lead Sponsor: Celgene Corporation

Target Recruit Count: 60

Registration Number: NCT00179712

Locations: 🇺🇸
Medical College of GeorgiaDept of OBGYN, Augusta, Georgia, United States
🇺🇸
University of MinnesotaObstetrics & Gynecology, MMC, Minneapolis, Minnesota, United States
🇺🇸
Ohio State University, Columbus, Ohio, United States

Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Topotecan

First Posted Date: 2005-09-15

Last Posted Date: 2014-05-14

Lead Sponsor: North Eastern German Society of Gynaecological Oncology

Target Recruit Count: 194

Registration Number: NCT00170677

Locations: 🇩🇪
Charité Campus Virchow-Klinikum, Berlin, Germany

Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer

Phase 1

Terminated

Conditions: Carcinoma, Renal Cell

Interventions: Drug: Topotecan
Radiation: Radiation therapy

First Posted Date: 2005-09-12

Last Posted Date: 2017-11-14

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 26

Registration Number: NCT00158886

Locations: 🇺🇸
GSK Investigational Site, Tampa, Florida, United States

a Multicenter Clinical Trial for the Treatment of Children and Adolescents With Soft Tissue Sarcoma Stage 4

Phase 2

Completed

Conditions: Sarcoma, Soft Tissue

First Posted Date: 2005-08-16

Last Posted Date: 2009-04-02

Lead Sponsor: Cooperative Weichteilsarkom Study Group

Target Recruit Count: 90

Registration Number: NCT00130858

Locations: 🇩🇪
Klinikum der Universität Kiel, Kiel, Germany
🇩🇪
Zentralkrankenhaus Bremen, Bremen, Germany
🇩🇪
Universitätsklinik der technischen Universität Dresden, Dresden, Germany

and more 30 locations

A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1a

Phase 1

Completed

Conditions: Neoplasms

First Posted Date: 2005-07-01

Last Posted Date: 2017-07-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 16

Registration Number: NCT00117013

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy